Find trials
Consejos para buscar

Placenta Study

Overview

Información sobre este estudio

The hypothesis of our research is that inflammatory mediators, including alarmins, are important cause of inflammation and poor functioning of the placenta.

Our overall objective is to obtain a better understanding of the mechanisms of action of inflammatory mediators on the placenta, as well as the mechanisms underlying these effects, and to identify new therapeutic targets and investigate their effectiveness in vitro.

More specifically we aim to:

  1. Determine in vitro the mechanisms and signaling pathways leading to inflammation and abnormal function of the placenta during exposure to alarmins and/or pathogenic agents (infections/pathogen associated molecular patterns) allowing the comparison between the two types of stimuli.

Following an uncomplicated cesarean delivery, the placenta will be acquired by the study team and approximately 40 grams of tissue will be collected by the study team and placed into maintenance medium. Samples will be transferred to the laboratory of Dr. Girard (Guggenheim 3) or Dr. Enninga (Guggenheim 6) for processing. Processing will include single cell isolation, explants, nucleic acid isolation and/or histology. If samples are to be kept, they will be stored deidentified in the lab of Dr. Girard (Guggenheim 3). Information regarding the samples will be kept in a password protected REDCap database.

Target patient accrual is 150 participants.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • Women who will give birth at Mayo Clinic by caesarean-section at term following an uncomplicated pregnancy.

Exclusion Criteria:

  • Multiple pregnancy.
  • Known presence of clinical infections (e.g., chorioamnionitis), congenital anomalies or maternal pathologies (i.e., diabetes, hypertension, preeclampsia).
  • Intrauterine growth retardation or fetal macrosomia.
  • Maternal age under 18 or over 50.
  • Maternal body mass index (BMI) of less than 18 and more than 40.
  • Pregnancy less than 37 weeks of completed gestation.

Eligibility last updated 2/2/22. Questions regarding updates should be directed to the study team contact.

 

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Sylvie Girard, Ph.D.

Abierto para la inscripción

Contact information:

Sylvie Girard Ph.D.

Girard.Sylvie@mayo.edu

More information

Publicaciones

Publications are currently not available

Otros temas en investigación

.
CLS-20533487

Mayo Clinic Footer